---
title: "ATX-304"
canonical_url: https://peptidelibrary.app/library/atx-304
description: "Investigational oral small-molecule AMPK activator, formerly O304, tested in two small human trials in type 2 diabetes and in obesity with prediabetes. Not FDA-approved. Prohibited in sport as an AMPK activator under WADA S4.4.1."
updated: 2026-10-05
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# ATX-304

ATX-304 (also called O304 or O-304) is an oral small-molecule AMPK activator (investigational). ATX-304, first described as O304, raises AMP-activated protein kinase (AMPK) activity without lowering cellular energy levels. Instead of binding the enzyme as an allosteric activator, it protects the activated, phosphorylated form (threonine 172) from being switched off by phosphatases, and it needs the upstream kinase LKB1 to work.

Investigational oral small-molecule AMPK activator, formerly O304, tested in two small human trials in type 2 diabetes and in obesity with prediabetes. Not FDA-approved. Prohibited in sport as an AMPK activator under WADA S4.4.1.

Also known as: O304, O-304.

Categories: Fat Loss, Longevity, GLP-1/Metabolic.

## Classification

- Type: Oral small-molecule AMPK activator (investigational)
- Mechanism class: AMPK Activator
- Development stage: In clinical development
- Regulatory class: Investigational, not FDA-approved

## Mechanism

ATX-304, first described as O304, raises AMP-activated protein kinase (AMPK) activity without lowering cellular energy levels. Instead of binding the enzyme as an allosteric activator, it protects the activated, phosphorylated form (threonine 172) from being switched off by phosphatases, and it needs the upstream kinase LKB1 to work. It also acts as a mitochondrial uncoupler, increasing cellular respiration. In mice it increased glucose uptake in skeletal muscle and heart and raised energy expenditure, and in rodents it does not cross the blood–brain barrier.

Targets: AMPK (pan-isoform), Mitochondrial respiration (uncoupling).

Origin: Synthetic thiadiazole small molecule from Betagenon AB and Umeå University, Sweden; now developed by Amplifier Therapeutics, a Cambrian Bio company.

## Properties

- Molecular formula: C16H11Cl2N3O2S
- Molecular weight: 380.2 g/mol
- CAS number: 1261289-04-6
- Half-life: Long; plasma levels did not reach steady state until about day 14 of daily dosing. No numeric human half-life has been published.
- Studied routes: Oral

## Evidence

- Evidence level: Limited Human Evidence
- Highest documented: Controlled human trials
- Human trials: 2
- Controlled human trials: 2
- Preclinical sources: 2
- Latest source: 2026

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Steneberg P et al. PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients. JCI Insight. 2018. 2018. Controlled human trial. Population: Adults with type 2 diabetes on metformin (n=65, ATX-304 and placebo arms). Fasting plasma glucose, HOMA-IR, blood pressure and calf-muscle microvascular perfusion; safety [Source](https://pubmed.ncbi.nlm.nih.gov/29925691/)
2. Thieroff-Ekerdt RI et al. 1782-P: Phase 1b Study of AMPK/Mitochondrial Activator ATX-304 in Prediabetic Obese Participants. Diabetes. 2026;75(Supplement_1). 2026. Controlled human trial. Population: Adults with obesity and prediabetes (n=23, randomised 2:1 to ATX-304 or placebo). Safety, pharmacokinetics, adiponectin, liver and visceral fat by MRI, resting metabolic rate [Source](https://doi.org/10.2337/db26-1782-P)
3. Ericsson M et al. AMPK activator O304 improves metabolic and cardiac function, and exercise capacity in aged mice. Commun Biol. 2021. 2021. Preclinical: animal or lab study. Population: Aged mice. Metabolic and cardiac function, exercise capacity. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/34795407/)
4. Holm E et al. AMPK activator ATX-304 reduces oxidative stress and improves MASLD via metabolic switching. JCI Insight. 2025. 2025. Preclinical: animal or lab study. Population: Mice on a choline-deficient high-fat diet. Fat mass, blood cholesterol, liver steatosis and fibrosis. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/40197369/)

## Safety

Side effects: Mostly mild adverse events, at a rate similar to placebo (phase 1b).

Risks: No long-term human safety data; Prohibited in sport under WADA S4.4.1 (AMPK activators); Research-chemical products are not the trial material; identity and purity are unverified.

Human safety basis: Limited human reports

Key limitations: Not approved by the FDA for any use..

## Regulatory status

ATX-304 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### What is ATX-304?

Investigational oral small-molecule AMPK activator, formerly O304, tested in two small human trials in type 2 diabetes and in obesity with prediabetes. Not FDA-approved. Prohibited in sport as an AMPK activator under WADA S4.4.1.

### How does ATX-304 work?

ATX-304 raises AMPK activity by protecting the enzyme’s activated, phosphorylated form from being switched off, rather than by lowering cellular energy levels, and it also acts as a mitochondrial uncoupler. In mice this increased glucose uptake in muscle and heart and raised energy expenditure.

### Is ATX-304 a peptide?

No. ATX-304 is a small synthetic molecule (C16H11Cl2N3O2S, about 380 g/mol) that is taken by mouth. It is listed here because it is sold and discussed alongside peptides such as MOTS-c.

### What are the side effects of ATX-304?

Human safety data are limited to two short trials. The 28-day trial described ATX-304 as well tolerated with no ECG abnormalities, and the 8-week phase 1b reported mostly mild adverse events at a rate similar to placebo, with none related to body temperature, flushing or heart rate. Long-term safety is unknown. This is reference information, not medical advice.

### Is ATX-304 FDA approved?

No. ATX-304 is an investigational drug that has been tested in small European trials and is not approved for any use anywhere. Products sold online under the name are research chemicals.

### Is ATX-304 banned in sport?

Yes. ATX-304 is not named on the WADA Prohibited List, but section S4.4.1 prohibits AMPK activators as a class at all times, alongside named examples such as AICAR and MOTS-c. Athletes should check the current list directly, since it is revised every year.

### What compounds are similar to ATX-304?

Compounds most often compared with ATX-304 include AICAR, MOTS-c, SLU-PP-332, BAM15 and 5-Amino-1MQ. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients — JCI Insight, 2018](https://pubmed.ncbi.nlm.nih.gov/29925691/)
- [Phase 1b Study of AMPK/Mitochondrial Activator ATX-304 in Prediabetic Obese Participants — Diabetes (ADA abstract 1782-P), 2026](https://doi.org/10.2337/db26-1782-P)
- [EU CT 2023-505967-36-00 — Phase 1B study of ATX-304 Na salt tablets (EU Clinical Trials Information System)](https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-505967-36-00)
- [AMPK activator O304 improves metabolic and cardiac function, and exercise capacity in aged mice — Commun Biol, 2021](https://pubmed.ncbi.nlm.nih.gov/34795407/)
- [AMPK activator ATX-304 reduces oxidative stress and improves MASLD via metabolic switching — JCI Insight, 2025](https://pubmed.ncbi.nlm.nih.gov/40197369/)
- [O304 is a mitochondrial uncoupler which extends C. elegans lifespan and induces vasorelaxation of rat mesenteric arteries — Chem Biol Interact, 2025](https://pubmed.ncbi.nlm.nih.gov/41130350/)
- [WADA Prohibited List 2026](https://www.wada-ama.org/en/prohibited-list)
- [O304 ameliorates hyperglycemia in mice by dually promoting muscle glucose effectiveness and preserving β-cell function](https://pubmed.ncbi.nlm.nih.gov/37626210/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
